Source link : https://www.newshealth.biz/health-news/proof-of-benefit-in-acute-mi-again-evades-an-sglt2-inhibitor/
ATLANTA — The SGLT2 inhibitor empagliflozin (Jardiance) did not exactly prevent deaths and heart failure (HF) events when initiated atop other standard therapies for acute myocardial infarction (MI), the EMPACT-HF trial found, but cumulative risk did go down. Between empagliflozin and placebo groups, there was no difference in time-to-first-event analysis of hospitalizations for HF or […]
Author : News Health
Publish date : 2024-04-07 12:29:02
Copyright for syndicated content belongs to the linked Source.